Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more

Recent & Breaking News (NYSE:JNJ)

Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals

PR Newswire October 13, 2021

Johnson & Johnson Announces Jessica Moore as Vice President of Investor Relations

PR Newswire October 12, 2021

Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021

PR Newswire October 12, 2021

Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference

PR Newswire October 11, 2021

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

PR Newswire October 6, 2021

Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine

PR Newswire October 5, 2021

Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes

PR Newswire September 28, 2021

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

PR Newswire September 21, 2021

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

PR Newswire September 16, 2021

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases

PR Newswire September 13, 2021

Battle Against Johnson & Johnson "Texas Two-Step" Ploy Moves to New Jersey

PR Newswire September 2, 2021

Outcry Continues to Grow for Johnson & Johnson to Resolve Talc-Cancer Claims After Latest Jury Verdict

PR Newswire August 31, 2021

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa

PR Newswire August 31, 2021

Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design

PR Newswire August 26, 2021

Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference

PR Newswire August 26, 2021

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

PR Newswire August 25, 2021

Ovarian Cancer Victims Ask Court to Block Johnson & Johnson's 'Texas Two-Step' Bankruptcy Plan

PR Newswire August 24, 2021

Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022

PR Newswire August 19, 2021

Johnson & Johnson Announces Completion of Codman Neurosurgery Divestiture to Integra LifeSciences Holding Corporation

PR Newswire October 2, 2017

Biotech Investors, Here's Your PDUFA Primer For October

Benzinga.com  September 28, 2017